A 5-year post-marketing safety study for dalfampridine extended release tablets in multiple sclerosis

Trial Profile

A 5-year post-marketing safety study for dalfampridine extended release tablets in multiple sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Oct 2015 New trial record
    • 22 Oct 2015 According to an Acorda media release, 5-year post-marketing safety data from this trial was presented at the 31st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.
    • 07 Oct 2015 According to an Acorda media release, 5-year post-marketing safety data from this trial will be presented at the 31st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top